Collin Hovinga, PharmD, M.S., FCCP, clinical associate professor at UT College of Pharmacy and Vice President of Rare Orphan and Pediatric Diseases at Critical Path Institute, was appointed to PCORI's Advisory Board for Rare Diseases (one of 7 members). These advisory boards consist of multidisciplinary teams across the health and health care community to advise PCORI’s research funding initiatives and related work. PCORI funds research that offers patients and caregivers the information they need to make healthcare decisions. Its scientific research portfolio is divided between two programs—Clinical Effectiveness and Decision Science (CEDS) and Healthcare Delivery and Disparities Research (HDDR). These programs support the US National Priorities for Health. At the university, Dr. Hovinga has been one of our champion IPE faculty facilitators since 2016 for our foundational IPE experiences.
